Australian ambassador visits CSL Behring
CSL Behring management welcomes Australian Ambassador to Germany Philip Green.
New R&D Campus in Marburg
Video: “Topping-out” milestone celebrated in Marburg for facility scheduled to open in 2022.
From immune system problems to bleeding disorders and more – plasma-based therapies treat many health conditions.
Agreement with uniQure on Haemophilia Gene Therapy
• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia …
Hemophilia B gene therapy
CSL closes commercialization and license agreement for Hemophilia B gene therapy.
A Network for the Orphans of Medicine
The future of rare disease diagnostics in the focus of science and industry